Overview

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Status:
RECRUITING

Trial end date:
2027-07-15

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants with RRMM having received 1 to 3 prior lines of therapy.

Phase:

PHASE2

Details

Lead Sponsor:

Sanofi

Treatments:

Acetaminophen
carfilzomib
Dexamethasone
Diphenhydramine
isatuximab
Methylprednisolone
montelukast